-
Subscribe
for Free
-
-
Our
Cities▾
-
Tech
Channels ▾
-
Meet the
Xconomists ▾
-
Managing Director, D.E. Shaw and Co., L.P.
-
Professor, Biochemistry and Biophysics, UCSF
-
Lecturer in Innovation and Entrepreneurship, MIT
-
Director, Knight Foundation
-
Meet All the Xconomists ›
-
Founder and CEO, Esperion Therapeutics
-
Professor of Computer Science, UC Berkeley
-
CEO, Renaissance Venture Capital Fund
-
CEO, Evernote
-
Our
Events ▾
-
|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
PneumRx Raises $33M
|
Wade Roush |
01/04/11 |
San Francisco
|
|
Tryton Medical Obtains $20,000,000 Series D Round
|
VentureDeal |
09/14/10 |
Boston
|
|
Facet Solutions Secures $2,100,000 New Round
|
VentureDeal |
04/23/10 |
Boston
|
|
Marathon and Zafgen Add to Series B Rounds, Athenahealth and Sermo Announce Partnership, Sensata Sets IPO Terms, & More Boston-Area Deals News
|
Erin Kutz |
03/03/10 |
Boston
|
|
Intrinsic Therapeutics Grabs $18M
|
Erin Kutz |
02/26/10 |
Boston
|
|
Intrinsic Therapeutics Obtains $18,000,000 New Funding Round
|
VentureDeal |
02/26/10 |
Boston
|
|
Direct Flow Medical Lands $40,000,000 Series C Financing
|
VentureDeal |
10/04/09 |
San Francisco
|
|
New England Venture Activity Rebounds Slightly in Q2—Region’s Top 10 Deals List
|
Ryan McBride |
07/21/09 |
Boston
|
|
Merck and Roche Back Adimab, Viral Contamination Closes Genzyme Plant, Interlace Ties on $20.5M, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
06/17/09 |
Boston
|
|
Interlace Sews Up $20.5M Series C Round
|
Roxanne Palmer |
06/15/09 |
Boston
|
|
Interlace Medical Inc Obtains $20,500,000 Series C Funding Round
|
VentureDeal |
06/15/09 |
Boston
|
|
Tryton Medical, Inc. Secures $14,000,000 Series C Funding
|
VentureDeal |
03/31/08 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.